Research paper
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917
Study answer
What this study found
Selenium did not reduce progression to prostate cancer in men with high-grade prostatic intraepithelial neoplasia. Three-year prostate cancer rates were 35.6% with selenium and 36.6% with placebo, with no significant difference after adjustment (P = 0.73) or unadjusted analysis (P = 0.86). In the endpoint-known subgroup, prostate cancer was diagnosed in 48 of 135 selenium participants and 49 of 134 placebo participants. A non-significant subgroup signal suggested possible benefit in the lowest baseline selenium quartile, but overall incidence, cancer aggressiveness, and end-of-study biopsy…
- Study & population
- Phase III, multicenter, randomized, placebo-controlled prevention trial in men aged 40 years or older with biopsy-confirmed high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
- Intervention
- Selenium was given orally as selenomethionine at 200 mg/d daily for 3 years or until prostate cancer diagnosis.
- Key limitation
- Follow-up was limited to 3 years, which may be too short for a prevention endpoint in this setting.
View source
Open PDFOriginal abstract
The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion markin…